

QUARTERLY INVESTMENT REVIEW

Global Developed Equity Allocation Fund

Performance returns (USD)

ANNUALIZED RETURNS (QUARTER-END)	Quarter-End	YTD	1-Year	3-Year	5-Year	10-Year	Since Inception
Global Developed Equity Allocation Fund (net)	-3.60	10.98	10.98	5.31	8.87	8.02	7.37
Global Developed Equity Allocation Fund (gross)	-3.47	11.57	11.57	5.87	9.44	8.59	7.93
MSCI World	-0.16	18.67	18.67	6.34	11.16	9.95	8.16
Value Add	-3.44	-7.69	-7.69	-1.03	-2.29	-1.92	-0.79

Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower. Gross of fees, expenses and transaction costs, if any. If these fees, expenses and costs were included, performance would be lower. **Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. To obtain performance information to the most recent month-end, visit www.gmo.com.** Returns include a substantial, one-time litigation settlement recovery received on December 16, 2024. This event contributed 1.23% to Q4 2024 and 1.42% to 2024 annual performance. Performance for other periods, including this date, was also positively impacted, sometimes materially. Without this recovery, performance would have been lower in both absolute terms and relative to the benchmark. Additional information is available upon request.

MAJOR PERFORMANCE DRIVERS

- Top-down asset allocation detracted significantly from relative performance for the quarter as, within Developed Markets, the portfolio is biased away from the U.S. market, which strongly outperformed. It was also a relatively poor quarter for the small allocation to Emerging Markets.
- Security selection was also negative, as a combination of Quality and Value had a challenging time in the U.S.

U.S. equities accounted for 47.2% of the total portfolio on average through the quarter, comprising 3.2% in U.S. Small Cap Value equity, 5.1% in U.S. Small Cap Quality equity, 8.0% in broad U.S. equity, 15.5% in U.S. Opportunistic Value equity, and the remainder in the Quality, Quality Cyclical, and Resources strategies. This leaves the portfolio 26.1% underweight U.S. equities in total, and this had a negative impact on relative performance for the quarter as the MSCI USA index returned 2.7%, outpacing MSCI World. Security selection in the U.S. was difficult as, in aggregate, our U.S. portfolio returned -1.6%. Underweight positions in Tesla (Consumer Discretionary), NVIDIA (Information Technology), Broadcom (Information Technology), Amazon (Consumer Discretionary), and Apple (Information Technology) made up the top five biggest individual detractors from relative performance for the quarter. On the flipside, underweight positions in Eli Lilly (Health Care) and Advanced Micro Devices (Information Technology) featured in the top five biggest individual contributors to relative performance at the total portfolio level.

Developed ex-U.S. equities accounted for an average weight of 48.2% of the portfolio for the quarter, including the dedicated Japan Value position and some exposure from the Quality, Resources, and Quality Cyclical strategies. This overweight position in Developed ex-U.S. had a negative impact on relative performance as the MSCI World ex-U.S. index returned -7.4%, lagging the MSCI World index. Security selection within Developed Markets was flat for the quarter and the portfolio also returned -7.4 in aggregate. An underweight position in Novo Nordisk (Denmark Health Care) and an overweight position in Panasonic Holdings (Japan Consumer Discretionary) featured in the top five biggest individual contributors, while no Developed ex-U.S. names featured in the top five biggest individual detractors from relative performance for the quarter.

Inception Date: 16-Jun-05

Performance for the year of inception is less than a full calendar year. Returns shown for periods greater than one year are on an annualized basis.

Risks: Risks associated with investing in the Fund may include: (1) Market Risk - Equities: The market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares. (2) Management and Operational Risk: The risk that GMO's investment techniques will fail to produce desired results, including annualized returns and annualized volatility. (3) Non-U.S. Investment Risk: The market prices of many non-U.S. securities (particularly of companies tied economically to emerging countries) fluctuate more than those of U.S. securities. Many non-U.S. markets (particularly emerging markets) are less stable, smaller, less liquid, and less regulated than U.S. markets, and the cost of trading in those markets often is higher than it is in U.S. markets. For a more complete discussion of these risks and others, please consult the Fund's Prospectus. **Performance Returns:** Annualized Returns may include the impact of purchase premiums and redemption fees. The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

Net Expense Ratio: 0.54%; Gross Expense Ratio: 0.61% Net Expense Ratio reflects the reduction of expenses from fee reimbursements. The fee reimbursements will continue until at least June 30, 2025. Elimination of this reimbursement will result in higher fees and lower performance. Gross Expense Ratio is equal to the Funds Total Annual Operating Expenses set forth in the Funds most recent prospectus dated June 30, 2024.

QUARTERLY INVESTMENT REVIEW

MAJOR PERFORMANCE DRIVERS CONT.

The exposure to Emerging Market equities has reduced considerably since the beginning of the year and represented 3.5% of the total portfolio weight on average during the quarter. This had a modest negative impact on performance as the MSCI Emerging Market index returned -8.0%, lagging the MSCI World index return of -0.2%, although security selection was solid as the portfolio returned -6.0%. An overweight position in YPF (Argentina Energy) featured in the top five biggest individual contributors to relative performance at the total portfolio level, while no Emerging Market names featured in the top five biggest individual detractors.

Portfolio weights, as a percent of equity, for the positions mentioned were: YPF (0.1%), Advanced Micro Devices (0.0%), Broadcom (0.0%), Tesla (0.0%), Apple (1.3%), Panasonic Holdings (0.5%), NVIDIA (0.3%), Eli Lilly (0.2%), Amazon (0.7%), and Novo Nordisk (0.0%).

QUARTERLY INVESTMENT REVIEW

PRODUCT OVERVIEW

The GMO Global Developed Equity Allocation Fund seeks to generate total return greater than that of the MSCI World Index.

The philosophy that underlies all of GMO's Asset Allocation investment strategies is the belief that, at times and in the short term, the pricing of asset classes can deviate from true intrinsic value but mean reverts to appropriate valuation levels over a complete market cycle. Using GMO's 7-Year Asset Class Forecasts, the Fund seeks to allocate to areas of the global equity markets we believe are most attractively valued. Our approach combines the best of GMO's top-down Asset Allocation views and bottom-up equity research to identify mispricings at both the asset class and individual security levels. The Fund allocates to equity strategies that are actively managed by other GMO investment teams with expertise and experience in security selection within their respective markets. The Fund is allowed to invest up to 10% (at time of purchase) in emerging market equities.

IMPORTANT INFORMATION

Benchmark(s): The MSCI World Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of global developed markets. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the funds prospectus. To obtain a prospectus please visit www.gmo.com. Read the prospectus carefully before investing.

The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO*

SINGAPORE

SYDNEY

TOKYO**

*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area

**Representative Office